Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00474929
Other study ID # LS0689
Secondary ID 07-000710LS0689
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date August 29, 2007
Est. completion date August 8, 2019

Study information

Verified date February 2019
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Sorafenib and everolimus may stop the growth of cancer cells by blocking blood flow to the cancer and by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I/II trial is studying the side effects and best dose of sorafenib and everolimus and to see how well they work in treating patients with relapsed or refractory non-Hodgkin's lymphoma, Hodgkin's lymphoma, or multiple myeloma.


Description:

OBJECTIVES:

- Determine the maximum tolerated dose (MTD) of sorafenib tosylate and everolimus in patients with relapsed or refractory non-Hodgkin's lymphoma, Hodgkin's lymphoma, or multiple myeloma.

- Determine the toxicity of this regimen in these patients.

- Evaluate the therapeutic activity of this regimen in these patients.

- Evaluate the pharmacokinetic interaction of this regimen.

- Correlate clinical (toxicity and/or tumor response or activity) effects with pharmacologic (pharmacokinetic/pharmacodynamic) parameters and/or biologic (correlative laboratory) results.

OUTLINE: This is a multicenter, dose-escalation, phase I study followed by a phase II study.

- Phase I (closed to accrual as of 2/10/2009): Patients receive oral sorafenib tosylate and oral everolimus on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of sorafenib tosylate and everolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 out of at most 6 patients experience a Dose Limiting Toxicity (DLT).

- Phase II: Patients receive oral sorafenib tosylate twice daily and oral everolimus once daily at the MTD determined in phase I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Blood and bone marrow are collected periodically during the study and analyzed by flow cytometry, immunohistochemistry, and enzyme-linked immunosorbent assay. Patients enrolled in phase I also undergo blood sample collection on days 8 and 15 during course 1 and on day 1 of each subsequent course for pharmacokinetic studies.

After completion of study treatment, patients are followed every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 103 patients will be accrued for this study.


Recruitment information / eligibility

Status Completed
Enrollment 103
Est. completion date August 8, 2019
Est. primary completion date November 5, 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years to 120 Years
Eligibility DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed diagnosis of 1 of the following:

- Multiple myeloma

- Non-Hodgkin's lymphoma

- Hodgkin's lymphoma

- Relapsed or refractory disease

- Measurable disease, as defined according to diagnosis as follows:

- Multiple myeloma, meeting 1 of the following criteria:

- Serum monoclonal protein = 1.0 g/dL

- Urine monoclonal protein = 200 mg by 24-hour electrophoresis

- Serum immunoglobulin free light chain = 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio

- Monoclonal bone marrow plasmacytosis = 30% (evaluable disease)

- Lymphoma, meeting 1 of the following criteria:

- Measurable disease by CT scan or MRI or PET/CT scan, defined as = 1 lesion that has a single diameter of = 2 cm OR tumor cells in the blood = 5 x10^9/L

- Skin lesions can be used if the area is = 2 cm in = 1 diameter and photographed with a ruler

- Lymphoplasmacytic lymphoma without measurable lymphadenopathy, meeting both of the following criteria:

- Bone marrow lymphoplasmacytosis with > 10% lymphoplasmacytic cells or aggregates, sheets, lymphocytes, plasma cells, or lymphoplasmacytic cells on bone marrow biopsy

- Quantitative IgM monoclonal protein > 1,000 mg/dL

- Not a candidate for known standard potentially curative therapy

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Life expectancy = 12 weeks

- ANC = 1,500/mm³

- Hemoglobin = 9 g/dL

- Platelet count = 75,000/mm³

- Bilirubin = 1.5 times upper limit of normal (ULN) OR direct bilirubin normal

- AST = 3 times ULN (5 times ULN if liver involvement)

- Creatinine = 2.5 times ULN

- INR < 1.5 or activated PTT < 1.5 times ULN (no concurrent anticoagulants)

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective barrier contraception during and for at least 2 weeks after completion of study treatment

- No uncontrolled infection

- No NYHA class III-IV congestive heart failure

- No unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months)

- No myocardial infarction within the past 6 months

- No uncontrolled hypertension, defined as systolic blood pressure (BP) > 150 mm Hg or diastolic BP > 90 mm Hg, despite optimal medical management

- No known HIV positivity

- No other active malignancy requiring treatment

- No inability to swallow

- No gastrointestinal (GI) function impairment or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative disease, uncontrolled nausea, vomiting, or diarrhea, malabsorption syndrome, or small bowel resection) or preclude use of oral medications

- No thrombolic or embolic events (e.g., cerebrovascular accident, including transient ischemic attacks) within the past 6 months

- No pulmonary hemorrhage or bleeding event = grade 3 within the past 4 weeks

- No severe or uncontrolled medical conditions or other conditions that would preclude study compliance

- No liver disease, such as cirrhosis, chronic hepatitis or chronic persistent hepatitis, or uncontrolled infections

- No serious nonhealing wound, ulcer, or bone fracture

- No evidence or history of serious bleeding diathesis or coagulopathy, such as hemophilia or von Willebrand's disease

- No significant traumatic injury within the past 4 weeks

- No known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus)

PRIOR CONCURRENT THERAPY:

- More than 3 weeks since prior myelosuppressive chemotherapy or biological therapy and recovered

- More than 4 weeks since prior major surgery or open biopsy

- Lymph node biopsy within past 4 weeks allowed

- Prior everolimus allowed

- No concurrent immunosuppressant therapy

- Concurrent stable chronic doses of steroids (= 20 mg of prednisone per day) for disorders other than lymphoma (i.e., rheumatoid arthritis, polymyalgia rheumatica, adrenal insufficiency, asthma) or for pruritus or fever associated with lymphoma allowed

- Concurrent corticosteroids at the lowest possible dose necessary to control symptoms in patients with CNS lymphoma allowed

- No concurrent CYP450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital), rifampin, or Hypericum perforatum (St. John's wort)

- No other concurrent immunotherapy, radiotherapy, or chemotherapy

- No concurrent chronic oxygen therapy

- No concurrent warfarin or heparin

- No other concurrent investigational therapy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
RAD001
Phase I: Dose level 0: RAD001 5mg every other day; Dose level 1: RAD001 5mg every day; Dose level 2: RAD001 5mg every day; Dose level 3: RAD001 10mg every day; Phase II: RAD001 5mg every day;
Sorafenib
Phase I: Dose level 0: Sorafenib 200 mg twice daily; Dose level 1: Sorafenib 200 mg twice daily; Dose level 2: Sorafenib 400 mg twice daily; Dose level 3: Sorafenib 400 mg twice daily; Phase II: Sorafenib 200 mg twice daily;

Locations

Country Name City State
United States Holden Comprehensive Cancer Center at University of Iowa Iowa City Iowa
United States Mayo Clinic Cancer Center Rochester Minnesota

Sponsors (2)

Lead Sponsor Collaborator
Mayo Clinic University of Iowa

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Reporting a Dose Limiting Toxicity (DLT) The Maximum Tolerated Dose (MTD) is defined as the dose level below the lowest dose that induces dose-limiting toxicity (DLT) in at least one-third of patients (at least 2 of a maximum of 6 new patients). Dose-limiting toxicity (DLT) is defined as an adverse event attributed (definitely, probably, or possibly) in first cycle to the study treatment and meeting the following criteria:
Grade 4 infection
Grade 4 ANC or PLT
Grade 3 or higher non-hematologic adverse event.
NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 will be used to assess adverse events. For this endpoint, the number of patients reporting a DLT event are tabulated.
First cycle (28 days) of study treatment
Primary Proportion of Confirmed Tumor Responses A confirmed response is defined to be a CR or PR noted as the objective status for eligible patients during cycles 1-12.
Complete Response (CR):
Multiple Myeloma (MM): Negative immunofixation of serum and urine, disappearance of soft tissue plasmacytomas, and normalization of free light chain (FLC) ratio.
Lymphoma: Disappearance of all clinical and radiographic evidence of disease, all lymph nodes of normal size (1.5 cm or less), no splenomegaly.
Partial Response (PR):
MM: 50% reduction of serum or urine M-protein or to less than 200mg/day, a 50% reduction in the difference between involved and uninvolved FLC, and 50% reduction in the size of soft tissue plasmacytoma.
Lymphoma: 50% or greater reduction in sum of the products of the dimension for nodal masses; no increase in liver, spleen or node size; no new sites of disease; and a 50% decrease in lymphocyte count if followed at baseline.
Up to 12 cycles of treatment
Secondary Survival Time Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier. Up to 3 years from registration
Secondary Progression Free Survival Progression Free Survival is defined as the time from registration to the earliest date documentation of disease progression or death. The distribution of time to disease progression will be estimated using the method of Kaplan-Meier. Up to 3 years from registration
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT04270266 - Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT01949883 - A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Phase 1
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Completed NCT04434937 - Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) Phase 2
Completed NCT01855750 - A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Phase 3
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT00775268 - 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1